VanEck Pharmaceutical ETF
PPH
47 hedge funds and large institutions have $122M invested in VanEck Pharmaceutical ETF in 2020 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 6 closing their positions.
29% more capital invested
Capital invested by funds: $94.5M → $122M (+$27.2M)
11.07% more ownership
Funds ownership: 40.57% → 51.64% (+11%)
0% more funds holding
Funds holding: 47 → 47 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
0% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 11
99% less call options, than puts
Call options by funds: $361K | Put options by funds: $24.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$31.6M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.86M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.62M |
| 4 |
IMC Chicago
Chicago,
Illinois
|
+$1.37M |
| 5 |
DI
DFPG Investments
Sandy,
Utah
|
+$715K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCI
Brinker Capital Investments
Berwyn,
Pennsylvania
|
-$5.06M |
| 2 |
Goldman Sachs
New York
|
-$2.81M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.4M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$808K |
| 5 |
OPS
Orion Portfolio Solutions
Omaha,
Nebraska
|
-$606K |
PPH Hedge Fund Activity: Q3 2020 in Review
47 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q3 2020, worth a combined $122M — up 29% from $94.5M a quarter earlier.
Fund positioning in PPH was balanced in Q3 2020: 6 funds opened new positions, 6 closed out, 11 added to existing stakes and 11 trimmed.
The largest buyer was Bank of America, adding an estimated $31.6M. The largest seller was Brinker Capital Investments, cutting an estimated $5.06M.
- 47 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q3 2020, unchanged from Q2 2020.
- Funds reported $122M of VanEck Pharmaceutical ETF stock for Q3 2020, up 29% quarter-over-quarter.
- 6 funds opened new VanEck Pharmaceutical ETF positions in Q3 2020 and 6 closed out, a net change of 0 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q3 2020 was Bank of America, an estimated $31.6M added.
- The largest VanEck Pharmaceutical ETF seller in Q3 2020 was Brinker Capital Investments, an estimated $5.06M sold.
Based on aggregated 13F filings for Q3 2020.